Krishna Institute of Medical Sciences Limited has utilized ₹1,084 crore of its ₹1,500 crore Qualified Institutional Placement (QIP) proceeds in the quarter ended June 30, 2026. The healthcare company directed the bulk of these funds toward debt reduction, fully repaying ₹910 crore of its own outstanding borrowings and deploying ₹130 crore toward subsidiary debt repayments. This rapid deployment marks significant progress against the placement document’s objective to utilize net proceeds of ₹1,476.45 crore by FY27.

The monitoring agency report, issued by CARE Ratings Limited on August 3, 2026, was reviewed by the Audit Committee of Krishna Institute of Medical Sciences Limited. The filing was submitted pursuant to Regulation 32(6) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, and Regulation 162A(4) of the SEBI (Issue of Capital and Disclosure Requirements) Regulations, 2018. Pritesh Rath, Associate Director at CARE Ratings, served as the authorized signatory for the report.

Fund Utilization Breakdown

The company allocated its initial utilization primarily to balance sheet optimization. The following table details the deployment of funds across various objects during Q1FY27:

Of the ₹130 crore utilized for subsidiary investments, ₹100 crore was deployed for Chalasani Hospitals Pvt Ltd and ₹30 crore for KIMS Hospital Bengaluru Pvt Ltd. The remaining ₹85 crore allocated for subsidiary debt repayment remains unutilized as of June 30, 2026.

General Corporate Purposes and Commingling

For General Corporate Purposes (GCP), the company utilized ₹44 crore. This included ₹22 crore for salaries and consultants, ₹20 crore invested in KIMS Hospital Bengaluru Private Limited, and ₹2 crore in Chalasani Hospitals. CARE Ratings noted a material disclosure regarding fund management: proceeds designated for GCP were transferred to the company’s and subsidiaries’ current accounts. Because these accounts are used for routine business transactions, the monitored proceeds were commingled with regular business funds. The monitoring agency highlighted this structure in its report, noting that while permissible under certain conditions, it reduces the visibility of specific fund tracking compared to segregated accounts.

Deployment of Unutilized Proceeds

As of June 30, 2026, ₹413.51 crore remained unutilized. In line with SEBI regulations allowing temporary investment in creditworthy instruments, the company deployed ₹360 crore into ICICI Prudential Mutual Funds. The remaining balance was held in bank accounts maintained with Kotak Mahindra Bank.

What the Numbers Show

The immediate and full repayment of ₹910 crore in parent company borrowings signals a strategic priority on deleveraging rather than operational expansion in the first quarter. While this strengthens the balance sheet, the commingling of GCP funds with routine operating accounts introduces a layer of complexity for investors tracking the precise utilization of capital raised. The retention of over ₹400 crore in low-risk liquid instruments suggests the company is maintaining liquidity buffers before committing to further long-term expenditures or subsidiary investments in subsequent quarters.

Krishna Institute of Medical Sciences Limited will host a conference call with analysts and investors on Tuesday, August 4, 2026, at 10:00 AM IST. The discussion will focus on the company's business strategy and future outlook following the declaration of its Q1FY27 financial results. This engagement provides stakeholders with direct access to management for insights into operational performance and strategic direction.

The disclosure was made pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The notice was submitted to the Bombay Stock Exchange Ltd and the National Stock Exchange on July 28, 2026. The call is being hosted by IIFL Capital, which has circulated the invitation details to market participants.

Key Management Participants

Key management personnel scheduled to participate in the conference call are listed below. Their presence ensures that both strategic and financial aspects of the Q1FY27 performance will be addressed comprehensively.

Dial-In Details

The conference call is accessible via toll-free numbers for both domestic and international participants. The access details are provided below.

A Diamond Pass registration is also available for enhanced access. For further information regarding the conference call, investors may contact Rahul Jeewani, Naman Bagrecha, Aman Goyal, or Vighnesh Indure at IIFL Capital. The company secretary and compliance officer, Dr. Nagajayanthi J. R., signed the disclosure document, confirming the accuracy of the intimation.